Abstract 1680P
Background
Chronic pain is reported by > 50% of patients recovering from breast cancer (BC). Adverse life experiences (ALEs) are associated with decreased psychosocial functioning in BC survivors, but their effect on pain has not been thoroughly explored. Sense of coherence (SOC) is the disposition to feel that life is predictable and manageable. Sense of danger (SOD) reflects expectations of harm from a particular event.
Methods
We are conducting a prospective study to assess if ALEs increase chronic adverse effects in patients with localized BC and identify mediating mechanisms. Patients are recruited before starting (neo)adjuvant oncological treatment and assessed periodically by validated questionnaires, including ALEs, SOC, SOD from BC, FACT-COG, FACT-ES, and brief pain inventory. Blood samples for inflammatory biomarkers are stored. This sub-study tested if ALEs are associated with baseline pain, measured as a composite score of pain intensity and interference, and examined the mediating role of SOC and SOD.
Results
Of 126 participants, 97 provided data on ALEs. Median age was 49 (range 23-75). 53.6% were treated in the neoadjuvant setting. Chemotherapy was planned for 62.9%. More ALEs correlated with more pain (r =. 34, p <. 001). Educational level and planned chemotherapy correlated with less pain. Serial mediation analysis revealed that after controlling for these variables, ALEs were indirectly associated with more pain through lower SOC followed by higher SOD from BC, CIs = 0.001, 0.103. Together, the model explained 38% of the variance in patients’ pain, F (5, 82) = 9.92, p <. 001. Age, BMI, CRP levels, and neutrophils to lymphocytes ratio were not associated with pain scores or with other study variables. Having surgery (vs planned surgery) was not associated with pain scores.
Conclusions
Exposure to a higher number of ALEs was associated with higher baseline pain in early BC patients before oncological treatment, mediated by decreased SOC and higher SOD from BC. These results stress the importance of addressing past trauma, sense of coherence, and sense of danger from BC to improve physical adverse effects such as pain. Further study will explore the effect of ALE, SOC, and SOD on pain persistence after adjuvant therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1627P - Long survivors after androgen deprivation therapy (ADT) with or without docetaxel for metastatic castration-sensitive prostate cancer (mCSPC): Long-term follow-up of GETUG-15
Presenter: Sarah Blanchet-Deverly
Session: Poster session 11
1628P - Factors influencing clinical and biological response in patients treated with [177Lu]Lu-PSMA-617 under France's early access program
Presenter: Vincent Habouzit
Session: Poster session 11
1629P - Lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) therapy in patients (pts) with prior Radium-223 (223Ra)
Presenter: Kambiz Rahbar
Session: Poster session 11
1630P - A multicenter retrospective study on the efficacy of anti-PD-(L)1 in microsatellite unstable (MSI-H) metastatic castrate-resistant prostate cancer (mCRPC)
Presenter: Sandra Van Wilpe
Session: Poster session 11
1632P - Impact of androgen pathway inhibitors on cognitive function in elderly patients with metastatic prostate cancer: Results from the COG-PRO trial
Presenter: Antoine Boué
Session: Poster session 11
1634P - Does lower serum testosterone predict metastases-free survival in nmCRPC patients treated with novel antiandrogens? A post-hoc analysis of SPARTAN and ARAMIS
Presenter: Xudong Ni
Session: Poster session 11
1635P - Validation of automated bone scan index as a progression endpoint in two phase III studies of metastatic castration resistant prostate cancer (mCRPC) patients
Presenter: Andrea Knezevic
Session: Poster session 11